Expansion of AI-Based Personalized Health Management Services and B2B Business

Targeting the Medical Device Market by Leveraging Global Production and Distribution Networks

Photo by CAS

Photo by CAS

View original image

CAS has announced plans to establish a smart healthcare platform that integrates medical devices and data services, with the unified healthcare brand 'nBody' at the forefront. This new initiative aims to move beyond the company's traditional focus on measurement instrument manufacturing by linking devices with AI-based health management services, thereby securing a new growth engine in the rapidly expanding digital healthcare market.


Founded in 1983, CAS has developed its business based on the localization of strain gauges and precision measurement technology using load cells, expanding into industrial, commercial, and home scale markets. More recently, the company has broadened its business scope to include smart factory and EPC weighing solutions.


The nBody project, which the company is driving forward, focuses on building a business model that combines healthcare devices with data platforms, moving beyond a structure centered on measurement device manufacturing.


CAS is expanding its lineup of medical devices and healthcare equipment, including professional and home-use body composition analyzers, blood pressure monitors, thermometers, nebulizers, smart scales, body fat analyzers, and blood glucose meters. The company also explained that it is pursuing related projects through collaboration with domestic medical device specialists.


The company is building a service based on the CAS Health App that enables integrated management of personal health data, including weight, body fat, muscle mass, blood pressure, and body temperature. There are also plans to provide tailored health reports for each user.


In the future, CAS intends to launch health management services and subscription-based offerings utilizing AI-driven data analysis, and to expand into API-based B2B operations linked with hospitals and fitness centers.


It is expected that if CAS successfully combines its robust hardware manufacturing capabilities with AI-based software technology, the company will become a digital transformation (DX) success story by evolving from a traditional manufacturer to a high value-added data platform business.


The company is also strengthening its production system. CAS stated that it is expanding its medical device production facilities primarily through its Jiaxing subsidiary in China, while its Yangju plant in Korea is responsible for K-GMP-based production and quality management.


CAS currently operates overseas subsidiaries in 11 countries and a network of over 500 dealers. The company plans to expand overseas sales of nBody products, particularly in key markets such as China, Vietnam, India, Turkey, and the United States.



A CAS representative said, "nBody is a platform for expanding our measurement technology into the digital healthcare sector," and added, "We will continue to broaden our medical device product lineup and enhance our global supply capabilities."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing